right on schedule heb news 10/8 2:30 am, another good one from doc c
Chronic Fatigue Patient Groups Report on Ampligen Treatment
PR Newswire - October 08, 1998 02:30
Patient Groups to Present Their Perspectives on Hemispherx Treatment Protocols at Upcoming American Association for Chronic Fatigue Syndrome Research Conference
NEW YORK, Oct. 8 /PRNewswire/ -- HEMISPHERX BIOPHARMA (Amex: HEB) stated that various patients, who have participated in its long-term treatment evaluation programs of Ampligen(R) for chronic fatigue syndrome (CFS), will present detailed first-hand accounts at the upcoming American Association for Chronic Fatigue Syndrome Research Conference in Boston, Massachusetts. The patient groups will speak at approximately 6 PM on Saturday, October 10, 1998, and Monday, October 12, 1998, at approximately 8 AM in the conference which is being jointly sponsored by the Massachusetts Medical Society and the Massachusetts Department of Public Health, Bureau of Communicable Disease Control. The scientific sessions will be held at the Hyatt Regency Hotel in Cambridge, Massachusetts.
Hemispherx Biopharma stated that it is conducting several advanced clinical tests in CFS, both in the United States and Europe. These clinical tests include a cost-recovery treatment protocol and a confirmatory Phase III randomized, placebo-controlled, multicenter, double-blind evaluation at various medical centers in the continental U.S. Because the CFS disorder damages multiple body systems, including first-line immunological defenses, the Hemispherx clinical studies employ a large series of outcome parameters (which provide comment on potential efficacy) as well as more than 200 measurements of potential drug side-effects. The patient perspectives are expected to provide further insight into presentations being made separately by clinical investigators (MD/PhDs) who are actively evaluating Ampligen with respect to quantitative safety and efficacy parameters.
The Company said it had recently received inquiries from patient groups as a result of erroneous claims made by Asensio and Company regarding alleged drug toxicities. The Company, which filed litigation against Asensio last week, said it was encouraging patients and doctors to attend the full scientific meetings or, if not possible, to obtain unedited video transcripts of the conference in order to obtain a comprehensive understanding of these matters.
Hemispherx, headquartered in Philadelphia, PA, is a biopharmaceutical company. The Company is engaged in the manufacture and global clinical development of new drug entities in the nucleic acid (NA) class for chronic viral diseases and disorders of the immune system including CFS (Chronic Fatigue Syndrome). |
